)

Puma Biotechnology (PBYI) investor relations material
Puma Biotechnology H.C. Wainwright 27th Annual Global Investment Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Product pipeline and commercial performance
NERLYNX is FDA-approved for extended adjuvant and metastatic HER2-positive breast cancer, sold in the US via specialty pharmacy and distributor channels, and internationally through partners with royalty agreements.
Q2 2025 net revenue reached $49.2 million, up from $44.4 million year-over-year and $43.1 million sequentially, with 2,608 bottles sold, reflecting consistent growth.
Dose titration strategies have improved NERLYNX tolerability, with 71% of patients starting at a reduced dose, enhancing patient experience.
US market includes about 28,300 early stage HER2-positive breast cancer patients, but guidelines recommend use in a high-risk HR-positive subset (~6,000 patients); EU label is more restrictive.
Q3 2025 guidance: $46–48M NERLYNX revenue, $2–3M royalties, $2–4M net income; full-year 2025 guidance: $192–198M sales, $20–24M royalties, $23–28M net income.
Clinical development and trial updates
NERLYNX is in a phase 1 trial combined with T-DXd (ENHERTU), showing promising tumor regressions, including in pancreatic cancer; more data expected next year.
Alisertib, an Aurora kinase A inhibitor, is in phase 2 for hormone receptor-positive, HER2-negative metastatic breast cancer and small cell lung cancer, with prior trials showing notable response rates and PFS improvements, especially in biomarker-defined populations.
Ongoing Alysca breast phase 2 trial is enrolling ahead of expectations, targeting patients post-CDK4/6 inhibitor and endocrine therapy; interim data expected late 2025 or early 2026.
In small cell lung cancer, alisertib plus paclitaxel showed PFS and OS benefits in biomarker-positive subgroups (MYC expression, RB1 loss), guiding future biomarker-driven development.
Alysca lung study is optimizing dosing with GCSF prophylaxis, aiming for higher exposure and safety, with a focus on biomarker selection for future enrollment.
Intellectual property and legal matters
NERLYNX patents extend to 2030–2031 for composition, use, and combinations; alisertib patents extend to 2029–2034, with potential for five-year extensions.
Legal action against AstraZeneca for EGFR T790M patent infringement resulted in a $107.5M award, but a subsequent ruling invalidated the patents; an appeal is ongoing.
Next Puma Biotechnology earnings date

Next Puma Biotechnology earnings date

The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
I can't remember the last time an app had such a positive impact on my investment process.
)
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
)
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
)
Frequently asked questions
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Explore our global coverage